Ankylosing spondylitis is ankylosing spondylitis, and the treatment for patients in the middle and late stages of ankylosing spondylitis is mainly based on medication, including non-steroidal drugs such as Celecoxib combined with anti-rheumatic drugs such as Liuzasulphapyridine and biologics such as Infliximab, etc. At the same time, strengthening the functional exercise, trying to improve the treatment of life, and needing to carry out surgical operation to improve the deformity of joints if necessary. Patients with middle to late-stage ankylosing spondylitis usually have spinal and peripheral joint dysfunction, or even joint deformity, which affects their life status. Treatment is based on the principle of controlling disease progression and improving life treatment. Treatment methods include drugs, functional exercises, surgery and so on. Drugs mainly include non-steroidal drugs, such as celecoxib, ibuprofen, etc., anti-rheumatic drugs, such as lorazepam, methotrexate, etc., and biological agents, such as recombinant human type II tumor necrosis factor receptor-antibody fusion protein and infliximab, etc., which usually require a combination of two or three drugs. In order to avoid impaired mobility caused by joint fusion after the middle and late stages, patients are required to perform more functional exercises to slow down the progression of the disease. If serious deformity such as scoliosis has already occurred, it can be treated by surgery. Ankylosing spondylitis is still incurable, and it is recommended that patients receive long-term, regular treatment under the guidance of a rheumatologist.